

Special Issue

Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors

Message from the Guest Editors

Immune checkpoint inhibitors (ICIs) have recently taken off as promising immuno-therapeutic methods that have slowed down the progress of various cancers and equipped patients with survival advantages. However, the long-term respondents tally is less than 20% of the population. This low response rate warrants the need for biomarkers which can dynamically provide insight into the possible response of patients to ICIs. Biomarkers are biological molecules that predict the pathological state of patients and the potential response they will elicit to ICIs. Predictive biomarkers play a crucial role in analyzing the effects of ICI therapy on patients and potentially filtering outpatients who will certainly benefit from ICIs. Potential biomarkers for cancer immunotherapy, such as PD-1/PD-L1, total mutation burden (TMB), and tumor-infiltrating lymphocytes (TILs), etc., may be used to assist future application of immunotherapy and patient selection in clinical practice. The aim of this Special Issue is to look into the emerging biomarkers for immune checkpoint inhibitors in tumors. We welcome both original research articles and reviews.

Guest Editors

Dr. Honglei Chen

Dr. Hitoshi Dejima

Dr. Min Peng

Deadline for manuscript submissions

closed (20 May 2023)



Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/121458

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)





Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National
University Hospital, Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).